NEUROCRINE BIOSCIENCES INC (NBIX)

US64125C1099 - Common Stock

133.37  +2.72 (+2.08%)

After market: 133.37 0 (0%)

News Image
6 days ago - Investor's Business Daily

Beam Therapeutics Stock Shows Healthy Relative Strength Improvement

In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday.

News Image
7 days ago - Investor's Business Daily

Alkermes Stock Gets RS Rating Upgrade; Profits Surge

In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday.

News Image
9 days ago - Investor's Business Daily

CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image
13 days ago - Investor's Business Daily

Amicus Therapeutics Stock Sees Improved Relative Strength Rating

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.

News Image
14 days ago - Investor's Business Daily

Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review

The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply.

News Image
15 days ago - Seeking Alpha

Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.03, revenue of $515.2M misses by $3.19M (NASDAQ:NBIX)

Neurocrine Biosciences reports Q4 earnings, beating EPS expectations but missing revenue estimates.

News Image
15 days ago - Neurocrine Biosciences, Inc.

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full year ended December 31, 2023...

News Image
16 days ago - Chartmill

Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.

Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?

News Image
16 days ago - Chartmill

NASDAQ:NBIX is not too expensive for the growth it is showing.

While growth is established for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), the stock's valuation remains reasonable.

News Image
a month ago - Neurocrine Biosciences, Inc.

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2023 financial results...

News Image
2 months ago - Investor's Business Daily

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

News Image
2 months ago - Neurocrine Biosciences, Inc.

Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on...

News Image
2 months ago - InvestorPlace

VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today

VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration.

News Image
2 months ago - Investor's Business Daily

Amgen Stock Sees Relative Strength Rating Improve To 74

Amgen stock  saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74.

News Image
2 months ago - Investor's Business Daily

Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study

On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before.

News Image
2 months ago - Investor's Business Daily

Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark

On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81.

News Image
2 months ago - Investor's Business Daily

Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher

On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.

News Image
2 months ago - InvestorPlace

3 Stocks at the Forefront of Medical Innovation

Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.

News Image
2 months ago - Seeking Alpha

Biggest stock movers today: Ansys, Rocket Lab, Nike, Cummins, NetEase (NASDAQ:ANSS)

Take a look at some of today's biggest stock gainers and losers, including Ansys (ANSS), Karuna Therapeutics (KRTX), Nike (NKE), NetEase (NTES) and AAR (AIR).

News Image
2 months ago - Investor's Business Daily

Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade

On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.

News Image
2 months ago - InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy in December

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

News Image
2 months ago - Seeking Alpha

Citi starts Neurocrine at neutral, sees stock as fairly valued (NASDAQ:NBIX)

Citi has initiated coverage of Neurocrine (NBIX) with a neutral rating, stating stock is fairly valued for the commercial prospects of its products. Read more here.

News Image
2 months ago - Investor's Business Daily

Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days

Cassava Sciences sees its Relative Strength Rating reach the 80-plus level.

News Image
3 months ago - Investor's Business Daily

TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating

TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93.

News Image
3 months ago - Investor's Business Daily

Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

News Image
3 months ago - Seeking Alpha

Neurocrine gets FDA breakthrough therapy status for crinecerfont (NASDAQ:NBIX)

Neurocrine Biosciences (NBIX) has received FDA breakthrough therapy designation for crinecerfont in the treatment of congenital adrenal hyperplasia. Read more here.

News Image
3 months ago - Neurocrine Biosciences, Inc.

Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it received Breakthrough Therapy designation from the U.S. Food and Drug...